{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:50:36Z","timestamp":1792158636175,"version":"4.4.0"},"reference-count":27,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Glofitamab was investigated with obinutuzumab\/rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (G\/R\u2010CHOP) in patients with relapsed\/refractory B\u2010cell non\u2010Hodgkin lymphoma (B\u2010NHL) who had \u22651 prior obinutuzumab\/rituximab\u2010containing therapy (NCT03467373). The primary end\u2010point was to determine the optimal biological dose of glofitamab with R\u2010CHOP. Using a modified continual reassessment method, glofitamab dose escalation was administered from cycle (C) 2\u2009day (D)8 (70\u2009\u03bcg, 1800\u2009\u03bcg, 10\u2009mg, 30\u2009mg), with G\/R\u2010 CHOP for 6\u20138 21\u2010day\u2009cycles. The 70 and 1800\u2009\u03bcg cohorts received fixed\u2010dose glofitamab; the 10 and 30\u2009mg cohorts received step\u2010up dosing (C2D8, 2.5\u2009mg; C2D15, 10\u2009mg; C3D8+, 30\u2009mg). Patients completing induction could receive glofitamab every 8\u2009weeks for \u22642\u2009years. Thirty\u2010one patients with follicular lymphoma (including transformed), mantle cell lymphoma or marginal zone lymphoma received treatment. The most common adverse events (AEs) were anaemia and fatigue (each 58.1%). Grade 3\/4 AEs occurred in 25 (80.6%) patients (serious AEs: 23 [74.2%]; grade 5 AEs: 4 [12.9%; mostly infections]). Sixteen (51.6%) patients experienced cytokine release syndrome (grade 1\/2,\n                    <jats:italic>n\u2009=<\/jats:italic>\n                    \u200912 [38.7%]; grade 3\/4,\n                    <jats:italic>n\u2009=<\/jats:italic>\n                    \u20094 [12.9%]). Complete metabolic response rate was 83.9%. Median progression\u2010free survival was not reached after 44.2\u2009months follow\u2010up. Glofitamab plus G\/R\u2010CHOP showed promising benefit in relapsed\/refractory B\u2010NHL, supporting future investigation of glofitamab (2.5\/10\/30\u2009mg) with R\u2010CHOP in untreated diffuse large B\u2010cell lymphoma.\n                  <\/jats:p>","DOI":"10.1111\/bjh.70741","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:02:43Z","timestamp":1787014963000},"page":"1651-1663","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Glofitamab in combination with immunochemotherapy in patients with relapsed\/refractory B\u2010cell non\u2010Hodgkin lymphoma: Phase 1b dose\u2010escalation study"],"prefix":"10.1111","volume":"209","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3975-2448","authenticated-orcid":false,"given":"William","family":"Townsend","sequence":"first","affiliation":[{"name":"NIHR Clinical Research Facility University College Hospitals London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3848-6136","authenticated-orcid":false,"given":"Nilanjan","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Atrium Health, Levine Cancer Institute, School of Medicine Wake Forest University  Charlotte North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3873-1741","authenticated-orcid":false,"given":"Martin","family":"Hutchings","sequence":"additional","affiliation":[{"name":"Rigshospitalet and University of Copenhagen  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1492-5966","authenticated-orcid":false,"given":"Michael","family":"Dickinson","sequence":"additional","affiliation":[{"name":"The Peter MacCallum Cancer Centre Royal Melbourne Hospital and The University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Tani","sequence":"additional","affiliation":[{"name":"Ospedale di Ravenna  Ravenna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1709-9492","authenticated-orcid":false,"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences Humanitas University and IRCCS Humanitas Research Hospital Humanitas Cancer Center  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Crump","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitkumar","family":"Mehta","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham  Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Marks","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Freiburg  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Weisser","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Munich  Penzberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Barrett","sequence":"additional","affiliation":[{"name":"Roche Products Ltd  Welwyn Garden City UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Wu","sequence":"additional","affiliation":[{"name":"Roche (China) Holding Ltd  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derrick","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Lechner","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Munich  Penzberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Baumlin","sequence":"additional","affiliation":[{"name":"F. Hoffmann\u2010La Roche Ltd  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pontus","family":"Lundberg","sequence":"additional","affiliation":[{"name":"F. Hoffmann\u2010La Roche Ltd  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max S.","family":"Topp","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum W\u00fcrzburg  W\u00fcrzburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115304"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2018.07.014"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2027612"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0455"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03175"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1295599"},{"key":"e_1_2_14_9_1","unstructured":"European Medicines Agency.Columvi summary of product characteristics. 2023. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/columvi\u2010epar\u2010product\u2010information_en.pdf. Accessed 11 May 2026."},{"key":"e_1_2_14_10_1","unstructured":"U.S. Food and Drug Administration.COLUMVI. 2023. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761309s000lbl.pdf. Accessed 11 May 2026."},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02403"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206913"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_14_14_1","unstructured":"Department of Health and Human Services.Common Terminology Criteria for Adverse Events (CTCAE) v4.03. 2010. Available from:https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010\u201006\u201014_QuickReference_8.5x11.pdf. Accessed 11 May 2026."},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148778"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7008"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000843772.15634.49"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01774-4"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00481"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-194333"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_433516"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S34273"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00033-3"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2025.100080"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621375"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-183100"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70094_280"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70741","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.70741","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70741","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:10:08Z","timestamp":1792156208000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.70741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1111\/bjh.70741"],"URL":"https:\/\/doi.org\/10.1111\/bjh.70741","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"assertion":[{"value":"2025-10-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}